Lerario, Antonio M <br/><br/>
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.  [electronic resource] 

 -  Hormones & cancer  Aug 2014 
 - 232-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1868-8500 
<br/><br/><label>Standard No.: </label>10.1007/s12672-014-0182-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenal Cortex Neoplasms--drug therapy<br/>Adrenocortical Carcinoma--drug therapy<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents, Hormonal--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Mitotane--administration & dosage<br/>National Cancer Institute (U.S.)<br/>Neoplasm Recurrence, Local--drug therapy<br/>United States<br/>Young Adult